Details for Patent: 10,583,110

Which drugs does patent 10,583,110 protect, and when does it expire?

Patent 10,583,110 protects JEVTANA KIT and is included in one NDA.

This patent has fifty-one patent family members in thirty-four countries.

Summary for Patent: 10,583,110

Title:	Antitumoral use of cabazitaxel
Abstract:	The invention relates to a compound of formula: ##STR00001## which may be in base form or in the form of a hydrate or a solvate, in combination with prednisone or prednisolone, for its use as a medicament in the treatment of prostate cancer, particularly metastatic prostate cancer, especially for patients who are not catered for by a taxane-based treatment.
Inventor(s):	Gupta; Sunil (Lexington, MA)
Assignee:	SANOFI MATURE IP (Paris, FR)
Application Number:	15/627,962
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,583,110
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,583,110

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sanofi Aventis Us	JEVTANA KIT	cabazitaxel	SOLUTION;INTRAVENOUS	201023-001	Jun 17, 2010	AP	RX	Yes	Yes						INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-AGONIST

International Family Members for US Patent 10,583,110

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	078824
Australia	2010310986
Australia	2015200149
Australia	2016200598
Australia	2017232227
Australia	2019203514
Brazil	112012011457